CureVac BV (CVAC) Stock Price Today
Key Stats
- $1.05BMarket Cap
- -Volume
- HealthSector
- $5.6052W High
- $2.5952W Low
- 36 DaysTypical Hold Time
- $599.28MEnterprise Value
- -Div Yield
- -Trading Activity
Track CureVac BV (CVAC) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, CureVac BV has traded between a low of $2.59 and a high of $5.6, highlighting its annual price range. Buy and sell CureVac BV shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About CureVac BV
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Most Recent News
Global CPaaS market to exceed $50B by 2031, led by Infobip, Twilio, and Sinch.
Juniper Research forecasts the global Communications Platform as a Service (CPaaS) market will more than double from $21 billion in 2026 to over $50 billion by 2031. Growth is driven by rising use of conversational AI, authentication, and new messagi...
Geely Auto Group's October sales top 310,000 vehicles, led by record new energy vehicle sales and strong export growth.
Geely Auto Group reported October vehicle sales of 310,183 units, surpassing 300,000 for the first time in 2026, marking eight consecutive months of year-over-year and month-over-month growth. New energy vehicles (NEVs) accounted for 69% of sales, re...
Elbit Systems wins $170M contract to build advanced artillery training center for Israel Defense Forces.
Elbit Systems has secured a $170 million contract from the Israel Ministry of Defense to develop and operate a state-of-the-art training and simulation center for the Israel Defense Forces Artillery Corps over 15 years. The center will support integr...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.